ResultsIQ

ResultsIQ › Latest results › Cohance Lifesciences Limited

Cohance Lifesciences Limited Q2 FY27 results deck summary

NSE: COHANCE · BSE: 543064

Results deck of 7 Nov 2026, summarised by AI from the filing.

Cohance's Q2 FY27 revenue fell 14.2% YoY to ₹4,767 mn, but adjusted EBITDA margin recovered to 9.6% and H2 is guided to grow YoY.

Key takeaways

  1. H2 outlook Management expects H2FY27 revenue and EBITDA to grow YoY, with H2 stronger than H1.
  2. Margin rebound Adjusted EBITDA margin improved to 9.6% in Q2FY27 from 2.2% in Q1FY27.
  3. Sapala growth Nucleic acid business Sapala grew 33.6% YoY in Q2 on demand for nucleic-acid building blocks.
  4. CDMO decline Pharma CDMO revenue fell 27.4% YoY in Q2 and 32.7% in H1, weighing on overall revenue.

Original filing on BSE

Cohance Lifesciences Limited Q2 FY27 results

As filed: Revenue ₹477 cr (−14% year on year), EBITDA ₹35.4 cr (−71% year on year), PAT ₹2.3 cr (−97% year on year), EBITDA margin 7.4% (−1,000 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 32% from last quarter. Share price after the results: +6.3% in 30 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
  • H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).

Past price moves after results do not indicate future moves. Not a recommendation.

Cohance Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.